The signature program: Bringing the protocol to the patient

B. P. Kang, E. Slosberg, S. Snodgrass, C. Lebedinsky, D. A. Berry, C. L. Corless, S. Stein, A. Salvado

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

Earlyâ € phase clinical development in oncology has evolved dramatically with the deciphering of the human genome in 2004. Genomic analysis and the tools identifying genetically disrupted pathways within a patient's tumor have been a driving force for personalized medicine and for the development of highly targeted novel therapies. Tumors are often genetically heterogeneous, with multiple concurrent genetic abnormalities. On the other hand, tumors arising from different tissues may share identical molecular drivers.

Original languageEnglish (US)
Pages (from-to)124-126
Number of pages3
JournalClinical pharmacology and therapeutics
Volume98
Issue number2
DOIs
StatePublished - Aug 1 2015

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Kang, B. P., Slosberg, E., Snodgrass, S., Lebedinsky, C., Berry, D. A., Corless, C. L., Stein, S., & Salvado, A. (2015). The signature program: Bringing the protocol to the patient. Clinical pharmacology and therapeutics, 98(2), 124-126. https://doi.org/10.1002/cpt.126